{{Rsnum
|rsid=4702473
|Gene=ADCY2
|Chromosome=5
|position=7528445
|Orientation=plus
|GMAF=0.4734
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ADCY2
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 39.8 | 40.7 | 19.5
| HCB | 24.1 | 48.9 | 27.0
| JPT | 26.5 | 49.6 | 23.9
| YRI | 13.6 | 46.9 | 39.5
| ASW | 7.0 | 63.2 | 29.8
| CHB | 24.1 | 48.9 | 27.0
| CHD | 11.0 | 59.6 | 29.4
| GIH | 34.7 | 48.5 | 16.8
| LWK | 13.6 | 52.7 | 33.6
| MEX | 17.2 | 60.3 | 22.4
| MKK | 14.7 | 55.8 | 29.5
| TSI | 44.1 | 49.0 | 6.9
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs4702473
|Name_s=
|Gene_s=ADCY2
|Feature=
|Evidence=PubMed ID:17537913
|Annotation=Risk or phenotype-associated allele: not stated Phenotype: Using a Quantitative Transmission Disequilibrium Test (QTDT), this variant was significantly associated with etoposide toxicity based upon IC50 values in cell lines from 30 parent-child trios. Study size: 87. Study population/ethnicity: 87 European descent Caucasians. Significance metric(s): p = 0.0000002. Type of association: FA; GN.
|Drugs=etoposide
|Drug Classes=
|Diseases=Drug Toxicity
|Curation Level=Curated
|PharmGKB Accession ID=PA165109319
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs4702473
|overall_frequency_n=75
|overall_frequency_d=128
|overall_frequency=0.585938
|n_genomes=43
|n_genomes_annotated=0
|n_haplomes=64
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | FTDNA2}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}